Phase II study of mitoxantrone and ketoconazole for hormone-refractory prostate cancer

Cancer
John EklundRaymond C Bergan

Abstract

Doxorubicin plus ketoconazole has exhibited significant activity in patients with advanced prostate cancer. However, overall and cardiac-specific toxicity was reported to be high. Mitoxantrone has activity similar to that of doxorubicin, is less cardiotoxic, and is widely used to treat prostate cancer. The current study sought to evaluate the toxicity and activity of mitoxantrone plus ketoconazole in a cohort of patients with hormone-refractory prostate cancer. Progression after medical or surgical castration and, for those patients receiving antiandrogens, progression after withdrawal was required, as was objective evidence of metastasis, castrate levels of testosterone, an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2, and intact cardiac function. After enrollment onto a multicenter local consortium study, subjects were treated with mitoxantrone at a dose of 12 mg/m2 intravenously every 3 weeks plus continuous oral ketoconazole at a dose of 400 mg 3 times daily and ascorbic acid at a dose of 250 mg. Replacement doses of hydrocortisone were given. For 40 enrolled subjects, the median prostate-specific antigen and ECOG performance status were 68 and 1, respectively, 53% had Gleason scores of 8 to 10, an...Continue Reading

References

Aug 1, 1989·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D L TrumpV C Jordan
Mar 1, 1989·Controlled Clinical Trials·R Simon
Jan 1, 1989·The Journal of Urology·T EichenbergerA Keating
Nov 1, 1982·Archives of Internal Medicine·A PontD A Stevens
Apr 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A SellaC J Logothetis
Jun 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·I F TannockK C Murphy
Sep 19, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G R HudesC McAleer
Nov 5, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G J BubleyG Wilding
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P W KantoffN J Vogelzang
Jun 6, 2003·Cancer Treatment Reviews·Cynthia L MartelPrimo N Lara
Jun 26, 2003·International Journal of Urology : Official Journal of the Japanese Urological Association·Karel OdrazkaEva Simakova
Mar 17, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eric J SmallNicholas J Vogelzang
Apr 15, 2004·European Urology·Simon Wilkinson, Gerald Chodak
Jul 1, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·William L DahutWilliam D Figg
Oct 8, 2004·The New England Journal of Medicine·Ian F TannockUNKNOWN TAX 327 Investigators
Oct 8, 2004·The New England Journal of Medicine·Daniel P PetrylakE David Crawford
Jan 22, 2005·CA: a Cancer Journal for Clinicians·Ahmedin JemalMichael J Thun

❮ Previous
Next ❯

Citations

Aug 3, 2012·Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology·Chung-Lin WangSheng-Nan Wu
Aug 12, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Irina VeytsmanTito Fojo
Nov 21, 2007·Bioorganic & Medicinal Chemistry Letters·Mariano A E Pinto-Bazurco MendietaRolf W Hartmann
Jun 5, 2007·Bioorganic & Medicinal Chemistry·Robert D Bruno, Vincent C O Njar

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.